Metabolic Research – perVial.com

Posted on October 7, 2026 by pervial

5-Amino-1MQ: Safety Profile, Regulatory Status, and Clinical Evidence Gaps

An evidence-based examination of 5-Amino-1MQ, reviewing its preclinical safety profile, current FDA regulatory standing, mechanism as a small-molecule NNMT

Posted on September 14, 2026 by pervial

MOTS-c: Preclinical vs. Human Evidence

3D render of mitochondrial DNA transcribing the MOTS-c peptide within a cellular signaling environment.

MOTS-c has gained widespread interest as a mitochondrial-derived peptide regulating metabolism and exercise capacity. However, a significant gap separates

Posted on September 5, 2026 by pervial

Retatrutide vs. Tirzepatide: How Triple Agonism Compares to Dual Agonism

3D scientific illustration of a multi-receptor agonist interacting with GLP-1, GIP, and glucagon receptors.

This comparative review examines retatrutide and tirzepatide, evaluating how retatrutide’s triple-receptor agonism (GLP-1, GIP, and glucagon) differs mecha

Posted on September 2, 2026 by pervial

5-Amino-1MQ: Preclinical Evidence, Translational Hurdles, and Research Gaps

3D visualization of the NNMT enzyme catalytic site interacting with a small molecule inhibitor and cellular metabolites.

5-Amino-1MQ is a synthetic small-molecule inhibitor of nicotinamide N-methyltransferase studied for metabolic regulation and muscle physiology. While roden

Posted on August 31, 2026 by pervial

Mazdutide Clinical Trials: Human Evidence, Efficacy, and Metabolic Outcomes

3D scientific visualization of a dual GLP-1 and glucagon receptor agonist interacting with cell membrane receptors.

Mazdutide (IBI362) is a dual GLP-1 and glucagon receptor co-agonist evaluated in Phase 2 and Phase 3 clinical trials. This evidence review examines publish

Posted on August 27, 2026 by pervial

Retatrutide Clinical Trials: Human Evidence, Efficacy, and Safety Findings

Microscopic visualization of a triple hormone receptor agonist interacting with cellular membrane receptor proteins.

Retatrutide clinical trials evaluate a novel triple-hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors. Phase 2 and Phase 3 data demonst

Posted on August 22, 2026 by pervial

Mazdutide as a Dual GLP-1/GCGR Agonist: Minto Pyramid Overview of Mechanisms, Clinical Efficacy, and Metabolic Impacts

3D scientific illustration of dual GLP-1 and glucagon receptor agonist Mazdutide molecular interactions

A structured Minto Pyramid analysis of Mazdutide (IBI362), detailing its dual GLP-1 and glucagon receptor agonism, glycemic and weight regulation, and hepa

Posted on August 22, 2026 by pervial

MOTS-c Peptide: Mechanisms, Preclinical Evidence, and Clinical Translation

3D scientific illustration of the MOTS-c peptide interacting with cellular metabolic pathways

A comprehensive review of MOTS-c peptide research, evaluating its cellular signaling mechanisms, preclinical metabolic findings, and current clinical statu

Posted on August 22, 2026 by pervial

Mazdutide (IBI362): Mechanisms, Clinical Data, and Metabolic Profile of Dual GLP-1/Glucagon Receptor Agonism

An evidence-based scientific overview of Mazdutide (IBI362), evaluating its dual GLP-1 and glucagon receptor co-agonism across in-vitro, preclinical, and h

Posted on August 22, 2026 by pervial

Survodutide (BI 456906): Dual GLP-1/Glucagon Receptor Agonist in Metabolic and MASH Research

3D scientific illustration of Survodutide dual GLP-1 and glucagon receptor agonist interaction

Survodutide is a dual GLP-1 and glucagon receptor agonist demonstrating potent efficacy across clinical trials for obesity, metabolic dysfunction, and stea